Table 4.
Concomitant medication use before onset of calcific uremic arteriolopathy adverse event
| Variable | Placebo (n=18) | Cinacalcet (n=6) |
|---|---|---|
| Vitamin D sterol use (%) | 72 | 100 |
| Median IV paricalcitol-equivalent dose (10%, 90% percentile) (μg/wk) | 15 (6, 24) | 10 (5, 45) |
| Phosphate binder use (%) | 100 | 100 |
| Calcium-containing phosphate binder use (%) | 67 | 83 |
| Study drug dose | ||
| Patients (n) | N/A | 5 |
| Median dose (10%, 90% percentile) (mg/d) | 30 (30, 180) | |
| Commercial cinacalcet dose | ||
| Patients (n) | 1 | NA |
| Median dose (10%, 90% percentile) (mg/d) | 30a | |
| Statin use (%) | 100 | 100 |
| Warfarin or other oral anti-coagulant use (%) | 50 | 33 |
| Erythropoietin agents (%) | 100 | 100 |
| Iron use (%) | 78 | 83 |
n refers to number of patients in the safety analysis set. Percentages are based on n. IV, intravenous; N/A, not available.
a
Single dose at 5 months before calcific uremic arteriolopathy onset.